Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Meiji Gains Japan Rights for Novel Blood Cancer Treatment from HUYA Bioscience
Meiji Seika Pharma said on January 9 that it will obtain exclusive rights from US-based HUYA Bioscience International to market the investigational anticancer agent HBI-8000 (tucidinostat) in Japan. Under the terms of the agreement, Meiji will also gain exclusive rights…
To read the full story
Related Article
- HUYA Files HBI-8000 for PTCL in Japan: Meiji
April 8, 2021
- HUYA Files Novel T-Cell Leukemia-Lymphoma Med in Japan
October 8, 2020
- With 2 New Deals Inked, Meiji Hunkering Down for Full-Scale Entry into Hematology Market
February 12, 2020
BUSINESS
- Daiichi Targets 3 Trillion Yen Sales by FY2030, Global Top-5 Oncology Spot
May 12, 2026
- Lilly Japan Hits Record Sales as Mounjaro Tops 100 Billion Yen
May 12, 2026
- Ferring Nabs Japan Approval for Bladder Cancer Gene Therapy
May 12, 2026
- Teijin to Offload Legacy Drug Portfolio as It Speeds Up Pivot to Rare Diseases
May 12, 2026
- Keytruda Extends Run as Japan’s Best-Selling Drug in April: Encise
May 12, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…